Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) announced that DAYBUE STIX, a powder formulation of its Rett syndrome treatment trofinetide, is now available in the United States. The U.S. Food and Drug Administration approved the new formulation in December 2025.

DAYBUE STIX is a dye- and preservative-free powder that can be mixed with water-based liquids for oral administration. The company stated the powder formulation is bioequivalent to the original DAYBUE oral solution, which was approved by the FDA in 2023.

The treatment is indicated for Rett syndrome in adults and pediatric patients two years of age and older. Rett syndrome is a genetic disorder that primarily affects girls and causes severe cognitive and physical disabilities.

"Initial feedback from a small group of caregivers following the limited launch revealed that more than 80% of early users reported satisfaction with DAYBUE STIX," said Tom Garner, Acadia's Chief Commercial Officer.

The powder comes in individual packets and can be mixed with various liquids including juice, tea, lemonade, or liquid hydration products. The company said this allows caregivers to customize the taste for patients.

The efficacy and safety data for DAYBUE STIX is based on the Phase 3 LAVENDER study conducted with the original oral solution formulation. A bioequivalence study demonstrated that both formulations provide comparable drug exposure.

Acadia offers a support program called Acadia Connect that provides assistance with financial resources and prescription support for patients and caregivers. The original oral solution formulation remains available for patients.